Background {#Sec1}
==========

A global incidence of esophageal cancer has increased by 50% in the past two decades. Each year, around 482,300 people are diagnosed with esophageal cancer, and 84.3% die of the disease worldwide \[[@CR1], [@CR2]\]. At present, the primary method of treating patients with esophageal cancer has been surgery. However, the traditional open esophagectomy (OE) procedure has high complication rates resulting in significant morbidity and mortality \[[@CR3], [@CR4]\]. Various studies showed in-hospital mortality between 1.2 and 8.8% \[[@CR4]--[@CR7]\], even as high as 29% \[[@CR8]\].

Minimally invasive oesophagectomy (MIO), which was first described in the 1990s \[[@CR9], [@CR10]\], was attributed to be superior in reducing postoperative outcomes, without compromising oncological outcomes and avoiding thoracotomy and laparotomy. The basis of minimally invasive techniques in esophageal surgery is to maintain the therapy effectiveness and quality of traditional operations, while reducing perioperative injury. Nevertheless, the real benefits of minimally invasive approach for esophagectomy are still controversial \[[@CR11]--[@CR13]\]. A number of meta-analyses and even randomized controlled trials demonstrated MIO to be superior in reducing risk of postoperative outcomes, but their results are not very consistent, especially on the issue of in-hospital mortality \[[@CR14]--[@CR30]\]. Furthermore, these studies ignored preoperative clinical data and other Chinese relevant literatures. We, therefore, performed a meta-analysis combining the relevant publications and comprehensively assess the superiority of MIO.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

MEDLINE, Embase, Science Citation Index, Wanfang, and Wiley Online Library were thoroughly searched with terms "Minimally Invasive Esophagectomy" or "Open Esophagectomy," "Esophagectomy,""MIE," "laparasc," "thoracosc," "VATS," "transhiatal" (date until May 2016). Relevant literatures containing full text were back tracked thoroughly, while abstracts and unpublished reports were excluded.

### Selections of studies {#Sec4}

#### Inclusion criteria {#FPar1}

The inclusion criteria are as follows: (1) randomized or non-randomized controlled studies with parallel controls, (2) comparison on OE versus MIO, (3) sufficient data of estimated odds ratios (ORs)/weighted mean difference (WMD) and 95% confidence intervals (CIs).

#### Exclusion criteria {#FPar2}

The exclusion criteria are as follows: (1) studies that were not compared or case report, (2) incomplete literature, and (3) overlapped studies.

### Data extraction {#Sec5}

Two investigators read all the included literatures carefully and extracted all the data, such as first author, published year, numbers of case and controls, outcomes of interest, etc. If two investigators have divergent ideas on any data, the third investigator would be asked to check and reach consensus on the data.

### Outcomes of interest {#Sec6}

Definition of MIO was thoracoscopic/laparotomy-assisted esophagectomy, hybrid minimally invasive esophagectomy, total thoracoscopic/hand-assisted thoracotomy, hand-assisted laparotomy, or minilaparotomy/laparoscopic esophagectomy.Preoperative clinical data included age, neoadjuvant therapy, comorbidity, TNM staging, and gender.Postoperative data contained operative duration, blood loss, intensive care unit (ICU) stay, hospital stay, and harvested lymph nodes.The complications are as follows. (1) Mortality included in-hospital mortality and 30-day mortality. (2) Pulmonary complications included pneumonia, respiratory failure, adult respiratory distress syndrome (ARDS), etc. (3) Cardiovascular complications included arrhythmia, heart failure, acute myocardial infarction, deep vein thrombosis, pulmonary embolism, etc. (4) Gastrointestinal complications included gastric tip necrosis, anastomotic stricture, delayed gastric emptying, gastric volvulus, etc. (5) Surgical technology related (STR) complications included splenic laceration, tracheal laceration, pneumothorax, chylothorax, hemorrhage, etc.

### Statistical analysis {#Sec7}

Data was analyzed using STATA 11 (Stata Corp LP, College Station, Texas, 2011). Fixed or random effects models \[[@CR31]\] were used. Odds ratio (OR) was used for categorical variables, while weighted mean difference (WMD) was used for continuous variables, such as operative time, harvested lymph nodes, and blood loss \[[@CR32]\]. *Q* test was used to check the heterogeneity among each study. If the heterogeneity was high (*I* ^2^ \> 50%), Random Effects Model was used to calculate the pooled OR/WMD. Otherwise, the fixed effects model was used \[[@CR33]\]. If the heterogeneity test was statistically significant, sensitivity analysis, subgroup analysis, and Galbraith Plot Analysis were performed to find out potential origin of heterogeneity. Egger's Test and Begg's Funnel Plot were used for diagnosis of potential publication bias \[[@CR34]\]. A *P* value \<0.05 was considered as statistical significance. Duval and Tweedie nonparametric "trim and fill" procedure was used to assess the possible effect of publication bias \[[@CR35]\].

The Newcastle Ottawa Quality Assessment Scale was used to assess the validity and quality of studies \[[@CR36]\], as recommended in the Cochrane Handbook \[[@CR37]\]. This scale assigns a star rating based on pre-specified criteria. A total number of quality star ranged from one (low quality) to nine (high quality). A maximum of one star can be attained for each category, except comparability, which has maximum of two stars. The more the stars, the higher is the quality of study.

Results {#Sec8}
=======

Study characteristics {#Sec9}
---------------------

A flow chart of the literature search process is shown in Fig. [1](#Fig1){ref-type="fig"}. A total of 1021 unique records were identified by search strategy; 917 records were excluded; 16 studies were meta-analyses or systematic overviews \[[@CR14]--[@CR19]\]; ten were review; and four were letter; nine studies did not compare the outcomes of interest \[[@CR3], [@CR5]--[@CR12]\], and six studies were duplicate to previous study. Therefore, 57 studies containing 15,790 cases (both MIO and OE) were included in this meta-analysis \[[@CR30], [@CR38]--[@CR93]\].Fig. 1Study flow chart explaining the selection of 57 studies included in the meta-analysis

Preoperative clinical data as well as quality star ranging from 6 to 8 are shown in Table [1](#Tab1){ref-type="table"}. Of 15,790 cases, 5235 (33.2%) were MIO and 10,555 (66.8%) were OE. Thirty one studies were done in European countries and 26 in Asian countries, where 13 were from China \[[@CR45]--[@CR57]\]. Moreover, 39 studies involved total MIE, 12 studies thoracoscopic-assisted MIE (TA), and seven studies were hybrid (TA + MIE). TNM staging were reported in 40 studies (6265 cases), where 1973 patients (64.4%) in the MIO group and 1042 patients (32.5%) in the OE group were of early stage (stages I and II), mainly male (78.4% (MIO) vs 68.3% (OE)).Table 1Characteristics of included studies in this meta-analysisStudyYearCountryCasesGender (M)Age, yearsNTNOSHybridPreoperative comorbidity (MIO/OE)TNM stage (MIO/OE)(MIO/OE)(MIO/OE)(MIO/OE)(MIO/OE)CardiovascularPulmonaryDiabetes0 + I + IIIII + IVNguyen2000USA18/367/2964 ± 12/67 ± 89/96MIENRNRNRNRNROsugi2003Japan77/7264/5763.7 ± 9 · 6/64 · ±9 · 3NR7TANRNRNRNRNRKunisaki2004Japan15/3012/2162.3 ± 8.1/63 ± 6NR6MIENRNRNRNRNRBernabe2004USA17/1416/1163.9 ± 13.5/64.1 ± 10.7NR6TANRNRNRNRNRVan den Broek2004Netherlands25/2019/1463 ± 8/64 ± 817/47TANRNRNR8/1017/10Braghetto2006Chile47/119NRNR0/08MIENRNRNR41/806/39Bresadola2006Italy14/148/1361.9 ± 7.7/59.3 ± 10.9NR6MIENRNRNR11/63/8Shiraishi2006Japan116/3794/3161.5 ± 8.1/66.5 ± 9.326/107HybridNRNRNRNRNRSmithers2007Australia332/114267/10464 (27--85)/62.5 (29--81)136/298Hybrid76/22NR27/4192/36118/75Benzoni2007Italy9/136/1163.6 ± 2.6/60.2 ± 2.46/68TANR2/4NR9/70/6Fabian2008USA22/4316/3163 (46--86)/61 (35--82)9/167MIENRNRNR14/257/19Parameswaran2009UK50/3045/2167 (47--81)/68 (47--81)32/128MIENRNRNR27/1723/13Saha2009UK16/2813/2465 (50--80)/64 (35--78)NR8MIENRNRNRNRNRZingg2009Australia56/9845/7166.3 ± 1.3/67.8 ± 1.140/488MIE4/713/356/1235/4721/42Pham2010USA44/4641/3363 ± 8.6/61 ± 10.729/236MIENRNRNR20/2020/19Perry2010USA21/2118/1769 ± 8/61 ± 9NR7MIENRNRNRNRNRHamouda2010UK51/2444/2362/6044/207MIENRNRNRNRNRSafranek2010UK75/4653/3860 (44--77)/64(41--74)71/347HybridNRNRNR31/2944/17Schoppmann2010Australia31/3125/2161.5 (36--75)/58.6 (34--77)15/78MIE6/810/81/118/1913/12Schröder2010Germany238/181198/15161.1 (60--62)/57.8 (56--59)144/666TANRNRNRNRNRMehran2011USA44/4443/4061.0 (42--79)/62.5 (38--83)31/307MIENRNRNR23/2116/20Berger2011USA65/5351/3861 (41--78)/62 (40--86)28/436MIENRNRNR52/4113/12Lee2011Japan74/6473/6159.7 ± 10.3/56.6 ± 11.647/528HybridNRNRNR54/4920/15Nafteux2011Belgium65/10152/8163 (41--82)/64 (29--82)NR8MIE11/246/136/12NRNRYamasaki2011Japan109/10787/9564.6 ± 8.5/64.7 ± 8.085/688TA20/2011/1310/6NRNRBiere2012Netherlands59/5643/4662 (34--75)/62 (42--75)59/568MIENRNRNR31/2615/19Maas2012Netherlands50/5041/3362.5 (57--69)/65 (57--69)23/138MIENRNRNR19/1931/31Briez2012France140/140110/117NR67/698TANRNRNR92/8948/51Kinjo2012Japan106/7987/7062.7 ± 7.4/63.3 ± 8.654/117MIENRNRNR65/4541/34Mamidanna2012UK1155/6347892/4870NRNR7MIE400/2234141/78290/598NRNRSihag2012USA38/7629/6161.4 ± 8.1/63.3 ± 9.325/467MIE6/168/13NR29/539/23Sundaram2012USA47/5738/5267.3 (42--79)/61.7 (34--84)35/408MIE33/42NR11/14NRNRTsujimoto2012Japan22/2721/2170 ± 5.4/67 ± 10.18/166TANRNRNR12/1410/13Javidfar2012USA92/16571/12265 (56--74)/68 (60--74)51/967MIE9/239/2322/3565/9627/69Bailey2013UK39/3132/2765 (37--78)/62 (38--78)33/317TANRNRNRNRNRIchikawa2013Japan152/163129/14563.8 ± 8.5/64.6 ± 8.654/648TA23/3521/2426/37101/8151/79Kitagawa2013Japan45/4735/4063 (47--77)/64 (39--83)8/117MIENRNR8/8NRNRNoble2013UK53/5343/4566 (45--85)/64 (36--81)13/118MIENRNRNRNRNRParameswaran2013UK67/1947/1564 (45--84)/64 (51--77)50/177HybridNRNRNR43/823/11Takeno2013Japan91/16677/14763.7/64.2NR8TANRNRNRNRNRKubo2014Japan135/74111/6064.1 ± 8.2/62.2 ± 7.222/47Hybrid12/39/7NR112/4123/33Schneider2014UK19/6146/1562.3 (35--74)/66.7 (45--79)7/456MIENRNRNR16/362/24Daiko2015Japan31/3328/2866 (49--78)/65 (49--76)NR7MIENRNRNR23/328/1Kauppi2015Finland74/7959/6866 (51--85)/63 (39--82)61/628MIE14/1712/1417/1328/2546/54Law1997China18/6313/5566 (43--80)/63 (36--84)NR7MIENRNRNR5/1513/45Chen2010China67/3845/2561 ± 7/66 ± 6NR7MIE15/410/39/242/1525/23Gao2011China96/7889/7058.5 ± 7.3/59.1 ± 6.4NR6MIENRNRNR54/4042/38Shen2012China76/7152/5060.9 ± 9/62.6 ± 8.7NR6MIENRNRNR41/4435/27Liu2012China98/10567/7162.3 ± 10.1/65.8 ± 7.6NR6MIE13/1840/376/851/4347/62Mao2012China34/3828/2662/60NR6TANRNRNR27/217/17Wang2012China260/322194/23261.6 ± 8.761.2 ± 8.837/446MIENRNRNR201/23459/88MU2014China176/142116/10660 (55--66)/59 (54--62)NR6MIENRNRNR120/10956/33Meng2014China94/8965/6359.7 ± 9.3/61.1 ± 6.7NR7MIE11/1427/3112/1056/5038/39Zhang2014China60/6148/4762.4 ± 8/61.8 ± 8.4NR6MIENRNRNR41/4219/19Chen2015China59/5942/4057 (41--72)/56 (48--71)NR7MIE4/21/02/356/553/4Yang2015China62/6245/4562 ± 9/62 ± 8NR7MIENRNRNR44/4318/19Li2015China89/31866/22773 (70--83)/73 (70--85)NR7MIENRNRNR64/18825/126*NT* neoadjuvant therapy, *NOS* Newcastle-Ottawa quality assessment scale, *MIO* minimally invasive oesophagectomy, including MIE,TA, and hybrid MIE, *OE* open esophagectomy, *MIE* total minimally invasive esophagectomy, *TA* thoracoscopic-assisted MIE, *Hybrid* hybrid minimally invasive oesophagectomy

Preoperative clinical data {#Sec10}
--------------------------

Fifty-seven studies reported patient's age. There was no statistical significance between two groups after pooled analysis (WMD = −0.343, 95%CI = −1.200 \~ 0.514, *P* ~*V*~ \< 0.433). Thirty-three studies (5243 cases) reported that the patients in MIE group received more neoadjuvant therapy (Table [3](#Tab3){ref-type="table"}, pooled OR = 1.364, 95% CI = 1.042 \~ 1.785, *P* ~*V*~ = 0.024). Sixteen studies reported preoperative comorbidity, where there was no statistical significance between two groups (*P* ~*V*~ \> 0.05).

Postoperative data {#Sec11}
------------------

Forty-six studies (6260 cases) reported that operative time was higher in MIO group (Table [3](#Tab3){ref-type="table"}, pooled WMD = 1.364, 95% CI = 10.912 \~ 37.943, *P* ~*V*~ \< 0.05). Forty studies (5285 cases) reported less blood loss in MIO group (WMD = −196, 95% CI = −255.195 \~ −136.926, *P* ~*V*~ \< 0.05). Duration of hospital stay (13,899 cases), including ICU stay (10,761 cases), were found to be significantly lower in MIO group (WMD = −1.599, 95% CI = (−2.680 \~ −0.518,*P* ~*V*~ \< 0.05 and WMD = −3.66, 95% CI = −4.891 \~ −2.428, *P* ~*V*~ \< 0.05). There was no significant difference between two groups in forty-six studies (6390 cases) reported for harvested lymph nodes (Table [3](#Tab3){ref-type="table"}, WMD = −1.275, 95% CI = −5.851 \~ 3.301, *P* ~*V*~ = 0.585). There was significant heterogeneity in the outcome among all the indices of postoperative data. Stratified analysis was performed according to ethnicity (Asian/Caucasian); however, heterogeneity still existed in subgroups. We then gradually removed small sample size, with emphasis on not altering the overall qualitative results.

Complications {#Sec12}
-------------

### MIO and total complications {#Sec13}

Thirty-five studies including 5991 cases reported total complications, where 41.5% (1206/2907) were allocated to MIE group and 48.2% (1486/3084) were allocated to OE group, with overall morbidity of 44.9% (2692/5991) (see Table [2](#Tab2){ref-type="table"}).Table 2Outcomes of complication in included studiesStudyTotalPulmonaryCirculatory systemDigestive systemALRLNPSTRMortalityMIO/OEMIO/OEMIO/OEMIO/OEMIO/OEMIO/OEMIO/OEMIO/OEMIO/OENguyenNR2/61/11/23/40/40/10/1Osugi25/2712/143/2NR2/111/94/4NRKunisakiNR0/1NRNR2/13/3NRNRBernabeNRNRNR7/8NRNRNRNRVan den Broek14/182/2NR3/52/32/32/4NRBraghetto18/727/220/34/63/170/21/03/13BresadolaNR1/21/0NR1/23/1NRNRShiraishiNR25/1213/9NR12/942/10NR6/5Smithers207/76106/4460/2483/917/118/025/147/3BenzoniNR0/2NR0/11/11/1NR0/1Fabian15/311/185/81/03/31/20/31/4Parameswaran24/154/20/33/14/16/05/4NRSaha3/6NRNRNR2/3NRNR0/2Zingg19/2017/33NRNR11/11NR2/22/6Pham34/2713/918/163/14/56/03/103/2Perry13/172/35/85/44/61/22/5NRHamoudaNR15/55/33/14/2NR3/0NRSafranekNR19/13NR17/411/110/15/53/1SchoppmannNR5/17NR0/11/84/133/4NRSchröderNRNRNRNR18/17NRNR7/11MehranNR14/159/918/811/6NRNRNRBerger31/3210/221/6NR9/6NRNR5/4LeeNR11/20NRNR10/18NRNR4/8Nafteux44/6117/4711/1313/65/10NR6/92/2Yamasaki26/387/153/60/26/417/203/50/2BiereNR14/351/11/07/41/81/13/1Maas21/339/133/6NR4/33/52/50/1Briez50/8322/60NR6/48/6NRNR2/10Kinjo54/5422/3110/58/911/1321/104/10NRMamidannaNR276/1419165/1035NRNRNRNR46/274SihagNR1/335/19NR0/2NR3/50/2Sundaram28/415/199/1926/104/41/110/112/1Tsujimoto13/162/10NR1/17/32/21/41/5JavidfarNR9/2629/5619/335/73/022/383/7BaileyNR15/184/91/01/0NR6/152/2Ichikawa94/11720/3317/384/514/2760/772/20/8KitagawaNR6/14NRNRNRNR13/202/1NobleNR14/1810/7NR5/2NR2/21/1Parameswaran42/127/22/114/2NR2/16/33/1Takeno39/69NRNRNRNRNRNR4/15Kubo57/3513/16NR2/010/737/1418/192/2Schneider7/13NRNRNRNRNRNR0/2Daiko10/12NRNRNR6/43/62/6NRKauppi37/4813/1517/275/145/50/412/11NRLawNR4/153/16NR0/24/8NRNRChenNR7/10NR2/01/0NR2/1NRGao31/3613/11NR7/127/62/41/22/3Shen32/285/69/81/116/147/22/30/1Liu22/385/214/133/52/43/43/51/3Mao14/160/21/60/18/15/3NRNRWang90/14512/2321/3611/1326/326/78/162/11MU28/226/4NRNR12/4NRNR1/1Meng24/419/244/112/26/74/43/41/4ZhangNR4/73/53/23/22/12/7NRChen14/192/43/5NR2/34/51/1NRYang19/31NRNRNRNRNRNRNRLi32/1378/519/342/519/4518/494/193/16*AL* anastomotic leak, *RLNP* recurrent laryngeal nerve palsy, *STR* surgical technology-related, *Mortality* in-hospital/30-day mortality

Low heterogeneity was found among studies (*I* ^2^ = 38.5%, *P* ~*Q*~ = 0.012), so the fixed effects model was used (see Table [3](#Tab3){ref-type="table"}). The pooled OR = 0.70, 95% CI = 0.626 \~ 0.781, *P* ~*V*~ \< 0.05 indicated total complication was significantly lower in MIO group (Fig. [2](#Fig2){ref-type="fig"}). Publication bias was assessed by Egger's Test and Begg's Funnel Plot; no publication bias could be discovered (*P* ~*E*~ = 0.178).Table 3Differences between MIO and OE surgery patientsVariablesNo. studiesWMD/OR (95%CI)*P* ~*V*~*P* ~*Q*~*I* ^2^ (%)*P* ~*E*~Age, years57 (*n* = 15790)−0.343 (−1.200, 0.514)0.433\<0.0568.10.059NT34 (*n* = 5138)1.364 (1.042,1.785)0.024\<0.0573.00.362Comorbidity Cardiovascular16 (*n* = 10337)0.913 (0.815,1.022)0.1120.03044.20.930 Pulmonary15 (*n* = 9779)0.949 (0.819,1.099)0.4850.88100.722 Diabetes15 (*n* = 9983)0.942 (0.798,1.111)0.4760.45700.082Operating time, min46 (*n* = 6260)24.427 (10.912,37.943)\<0.05\<0.0596.10.155Blood loss, ml40 (*n* = 5285)−196.060 (−255.195,-136.926)\<0.05\<0.0598.90.592LN harvest46 (*n* = 6390)−1.275 (−5.851,3.301)0.585\<0.0599.80.786LOS, day45 (*n* = 13899)−3.660 (−4.891,-2.428)\<0.05\<0.0586.00.175ICU stay, day27 (*n* = 10761)−1.599 (−2.680, −0.518)0.004\<0.0598.20.078ComplicationTotal complication35 (*n* = 5991)0.700 (0.626,0.781)\<0.050.01238.50.178Pulmonary50 (*n* = 14781)0.527 (0.431, 0.645)\<0.05\<0.0560.3\<0.05Circulatory system36 (*n* = 12883)0.770 (0.681,0.872)\<0.050.4272.40.386Digestive system21 (*n* = 4081)1.097 (0.835,1.442)0.5070.08331.70.664AL50 (*n* = 7528)1.023 (0.870,1.202)0.7850.3048.50.018RLNP37 (*n* = 5429)1.108 (0.917,1.339)0.2890.08924.80.014STR39 (*n* = 5991)0.639 (0.522,0.781)\<0.050.91800.206Mortality38 (*n* = 14132)0.668 (0.539,0.827)\<0.050.94400.508*NT* neoadjuvant therapy, *LN* lymph node, *LOS* length of hospital stay, *ICU* intensive care unit, *AL* anastomotic leak, *RLNP* recurrent laryngeal nerve palsy, *STR* surgical technology-related, *Mortality* in-hospital/30-day mortality, *P* ~*V*~ the *P* value for pooled, *P* ~*Q*~ the *P* value for *Q* test, *P* ~*E*~ the *P* value for Egger's test Fig. 2Meta-analysis for MIE and total complications

### MIO and pulmonary complications {#Sec14}

Fifty studies including 14,781 cases reported pulmonary complications, where 17.1% (813/4761) were in MIO group and 22.6% (2264/10,020) were in OE group, with overall morbidity of 20.8% (3077/14,781).

There was very strong evidence of reduced risk of pulmonary complications in the MIO group (OR = 0.527, 95%CI = 0.431 \~ 0.645, *P* ~*V*~ \< 0.05), with statistical heterogeneity (*I* ^2^ of 60.3%, *P* ~*Q*~ = 0.012) (Fig. [3](#Fig3){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). In order to find out other sources of heterogeneity, Galbraith Plot Analysis was performed to identify which study results in the heterogeneity (Fig. [4](#Fig4){ref-type="fig"}). Pham et al. \[[@CR52]\] and Mamidanna et al. \[[@CR66]\] were outliers from the Galbraith Plot Analysis and *I* ^2^ values decreased after removing the study (OR = 0.502 95% CI = 0.425 \~ 0.592, *P* ~*V*~ \< 0.05, *I* ^2^ = 26.6%, *P* ~*Q*~ = 0.05). However, the funnel plot figure (Fig. [5](#Fig5){ref-type="fig"}) showed significant statistical difference (*P* ~*E*~ \< 0.05), indicating the possibility of publication bias.Fig. 3Meta-analysis for MIE and pulmonary complications Fig. 4Galbraith plot of MIE and pulmonary complications Fig. 5Begg's Test of MIE and pulmonary complications

### MIO and mortality {#Sec15}

Thirty-eight studies addressed the mortality (MIO 4379 vs OE 9753). The mortality risk was 3.8% (124/4379) in MIO group versus 4.5% (437/9753) in OE group. There was very strong evidence of reduced mortality in MIO group (OR = 0.668, 95% CI = 0.539 \~ 0.827, *P* ~*V*~ \< 0.05), with statistical homogeneity (*I* ^2^ of 0%, *P* ~*Q*~ = 0.944) (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Meta-analysis for MIE and Mortality

### MIO and cardiovascular complications {#Sec16}

Thirty-six studies reported cardiovascular complications (MIO 3745 vs OE 9138). There was very strong evidence of reduced cardiovascular complications in MIO group (OR = 0.770, 95% CI = 0.681 \~ 0.872, *P* ~*V*~ \< 0.05), with statistical homogeneity (*I* ^2^ of 2.4%, *P* ~*Q*~ = 0.427) (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Meta-analysis of MIE and cardiovascular complications

### MIO and surgical technology related (STR) complications {#Sec17}

Thirty-nine studies reported STR complications (MIO2933 vs OE 3058). There was very strong evidence of reduced STR complications in MIO group (OR = 0.770, 95% CI = 0.681 \~ 0.872, *P* ~*V*~ \< 0.05), with statistical homogeneity (*I* ^2^ of 2.4%, *P* ~*Q*~ = 0.918) (Fig. [8](#Fig8){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}).Fig. 8Meta-analysis of MIE and STR complications

### MIO and gastrointestinal complications {#Sec18}

Twenty-one studies reported gastrointestinal complications (MIO 1872 vs OE 2209). There was no evidence of reduced gastrointestinal complications in MIO group (OR = 1.097, 95% CI = 0.835 \~ 1.442, *P* ~*V*~ = 0.507), with statistical homogeneity (*I* ^2^ of 31.7%, *P* ~*Q*~ = 0.083) (Table [3](#Tab3){ref-type="table"}).

### MIO and anastomotic leak (AL) {#Sec19}

Fifty studies reported anastomotic leak (MIO 3680 vs OE 3848). There was no evidence of reduced anastomotic leak in MIO group (OR = 1.023, 95% CI = 0.870 \~ 1.202, *P* ~*V*~ = 0.785), with statistical homogeneity (*I* ^2^ of 8.5%, *P* ~Q~ = 0.304) (Table [3](#Tab3){ref-type="table"}).

### MIO and recurrent laryngeal nerve palsy (RLNP) {#Sec20}

Thirty-seven studies reported recurrent laryngeal nerve palsy (MIO 2624 vs OE 2805). There was no evidence of reduced RLNP in MIO group (OR = 1.108, 95% CI = 0.917 \~ 1.339, *P* ~*V*~ = 0.289), with statistical homogeneity (*I* ^2^ of 24.8%, *P* ~Q~ = 0.089) (Table [3](#Tab3){ref-type="table"}).

### Publication bias analysis {#Sec21}

Publication bias was assessed by Egger's Test and Begg's Funnel Plot. Begg's Funnel Plot is shown in Fig. [5](#Fig5){ref-type="fig"}, with significant statistical difference (*P* ~*E*~ \< 0.05) (Table [3](#Tab3){ref-type="table"}). This indicated the possibility of publication bias, so sensitivity analysis using "trim and fill" method was carried out, with the aim to impute hypothetically negative unpublished studies, to mirror the positive studies that cause funnel plot asymmetry \[[@CR35]\], and to show consistent and stable results between MIO and pulmonary complications (Fig. [9](#Fig9){ref-type="fig"}), anastomotic leak, and recurrent laryngeal nerve palsy.Fig. 9The "trim and fill" method for MIE and pulmonary complications

### Sensitivity analysis {#Sec22}

As sample size for cases and controls in all studies is not same (ranging from 9 to 6347), we gradually removed small sample size without altering the qualitative overall results. According to the sensitivity analysis shown in Fig. [10](#Fig10){ref-type="fig"}, we removed the Mamidanna et al. \[[@CR66]\], without alteration, where *I* ^2^ values decreased, indicating that the results were stable.Fig. 10The sensitivity analysis of MIE and pulmonary complications

Discussion {#Sec23}
==========

MIO has been investigated for decades and is considered to be advantageous compared to OE. However, in the previous studies, the analyzed groups of patients who underwent MIO were small and the reports were mostly retrospective comparative studies, and there was no consensus as to which operative method is superior \[[@CR94]\]. Therefore, an updated meta-analysis is performed, which includes the largest and the most complete collections of published data.

We found higher operative duration in the MIO group, consistent with Kunisaki's \[[@CR40]\], Shiraishi's \[[@CR45]\], and randomized controlled trials \[[@CR30]\] reported, perhaps due to surgeons' familiarization with a new and complex techniques. Blood loss in the MIO group was found to be lower compared with OE, in accordance with the results of several case reported and recently published meta-analyses \[[@CR14], [@CR20]\].

A shorter hospital stay in the MIO group indicated a faster postoperative recovery than OE group, consistent with other published meta-analyses \[[@CR14], [@CR20], [@CR21], [@CR30]\].

We did not find a significant number of harvested lymph nodes in the MIO group \[[@CR23]\]. However, significant heterogeneity was seen among all indices of postoperative data, explained by the fact that postoperative data are dependent on operator and tumor characteristics.

Total complication rates varied between 20.5 and 63.5% (Table [2](#Tab2){ref-type="table"}). The MIO group showed lower total complication rates, pulmonary complications occupying the major part. However, a number of studies have reported significantly lower pulmonary complications for those who underwent MIO 17.1% (813/4761) versus OE 22.6% (2264/10,020), with overall morbidity of 20.8% (3077/14,781), consistent with the result of 3.1--37.0% from other studies \[[@CR15]--[@CR20], [@CR45], [@CR58]--[@CR76], [@CR95]\].

Kinugasa et al. and Ferguson et al. \[[@CR95], [@CR96]\] noted that development of pneumonia post procedure was associated with worse prognosis for overall survival (*P* \< 0.01). In addition, Dumont et al. \[[@CR97]\] also showed that two thirds of all fatal complications were respiratory in nature. Sauvanet et al. \[[@CR98]\] reported that pulmonary morbidity was associated with age \>60, with no significant differences in two groups.

The pooled OR of 0.527 showed MIO to be more advantageous than OE in reducing pulmonary morbidity. Although statistical heterogeneity and publication bias were found, we demonstrated the superiority of MIO through statistical methods. However, several factors have been associated with pulmonary complications post procedure, including preoperative status, intraoperative details, and postoperative details \[[@CR99]\].

Gex et al. reported that overall 30-day mortality rate was 4.3% between 2004 and 2009, compared with 7.6% in 2002 and 2003, and 11.7% in 1997 and 1999 \[[@CR100]\]. Our study found the overall 30-day mortality rate of 5.8% and the pooled OR of 0.668, showing that MIO to be advantageous than OE in reducing mortality. The main advantages of MIO over conventional OE are minimal trauma, small incision, less blood loss, etc. \[[@CR6]\]. Other factors independently associated with 30-day mortality included TNM staging, preoperative neoadjuvant therapy, comorbidity, diabetes, increased age, and intraoperative blood loss. However, there was no difference between two groups in terms of age and comorbidity. We found increased number of patients having neoadjuvant therapy in MIO group and patients selected for MIO were always in the early stages. The bias in the selection of patients may have influenced the accuracy of the conclusion, which should be taken into consideration.

Arrhythmia, heart failure, pulmonary embolism, and other cardiovascular complications are recognized as common problems that caused significant morbidity and mortality. Zhou et al. \[[@CR24]\] reported significant decrease in the morbidity of arrhythmia and pulmonary embolism in MIO group. Corresponding to this, (see Table [3](#Tab3){ref-type="table"}), we found MIO to be superior to OE in reducing morbidity of system complications, according to the pooled OR = 0.777. Weidenhagent et al. \[[@CR101]\] also indicated that the perforation from minimally invasive surgery as such could decrease the risks leading to arrhythmia.

Rizk et al. \[[@CR102]\] indicated that "surgical technology related complications," defined as complications caused directly by operative techniques, had no relationship with overall survival post procedure. However, in our meta-analysis, we found strong evidence of reduced risk of STR complications in the MIO group.

Anastomotic leakage (AL) is a serious complication of esophageal resection and is associated with significant morbidity and mortality \[[@CR4]\]. In accordance with Zhou et al's conclusion \[[@CR17]\], we also did not find the evidence of reduced risk of anastomotic leak in the MIO group. Similarly, we also did not find any significant differences in two groups in terms of RLNP and gastrointestinal complications.

Although we conducted comprehensive meta-analysis, our study still has its limitations. (1) Out of 57 studies, only one study is randomized controlled trial (RCT), while others were case-control or cross-sectional designs. Seven studies were of small sample size, which might have influenced the final results of our study. (2) Patients selected for MIO are unlikely to have been representative of the general population of esophageal cancer. We found more patients having neoadjuvant therapy in MIO group, and the patients selected for MIO were always in the early stages, creating selection bias. (3) In order to highlight the advantages of MIO, surgeons would prefer to publish positive results, and unsatisfactory results may have been less inclined in their papers; all these can lead to publication bias. (4) In our study, we compared MIO with OE. MIO consists of different procedures. Although we performed a subgroup analysis according to different procedures, the results were also not qualitatively altered. However, lots of differences exist among these procedures, which will affect the quality of this meta-analysis, and the learning curve of MIO is quite steep, which may influence the outcome of MIE. These limitations may result in an overestimation or underestimation of the effect of MIO.

In addition, 19 studies did the follow-up visit, and all those studies indicated that the 3-year survival, 5-year survival, and overall recurrence rate did not differ between the two groups. Due to the difficulty in data extraction, no pooled analysis was performed, which may have influential role in this study.

Conclusions {#Sec24}
===========

In summary, this meta-analysis indicates that MIO is a feasible and a reliable surgical procedure and is superior to OE, with less perioperative complications and in-hospital mortality. However, due to certain limitations of this study, as aforementioned above, further large sample and RCT studies are needed to estimate the effect of MIO and establish the guidelines for future.

MIE

:   Minimally invasive esophagectomy

MIO

:   Minimally invasive oesophagectomy

OE

:   Open esophagectomy

RLNP

:   Recurrent laryngeal nerve palsy

STR

:   Surgical technology related

TA

:   Thoracoscopic assisted
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